|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Več možnosti |
|
|
© 2024 SFX by Ex Libris Inc. | Piškotki
CrossRef Omogočeno
|